

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2800708
<b>Application Number:</b>	10521064
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6846
<b>Title of Invention:</b>	Injectable depot formulation comprising crystals of iloperidone
<b>First Named Inventor/Applicant Name:</b>	Dierk Wieckhusen
<b>Customer Number:</b>	23550
<b>Filer:</b>	Stephen Franklin Swinton
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	VAND-0022-US
<b>Receipt Date:</b>	01-FEB-2008
<b>Filing Date:</b>	12-JAN-2005
<b>Time Stamp:</b>	15:30:30
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 120
RAM confirmation Number	684
Deposit Account	500999
Authorized User	SWINTON, JR.,STEPHEN F

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional fees required under 37 CFR 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed	VAND-0022-US_Supplemental_IDS_02-01-08-PRIMO.pdf	30838 2b4bc417d94137c0887f8c6b0711451d ba02a7f0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	NPL Documents	Blagden_CrystalEngineering ofActivePharmaceutical_PA. pdf	1155333 8c8ccb3da7bd5d04a7f9a04a65db01bfc 8b8ba5d	no	14
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	LinguaLinxCertificateOfTrans lationAccuracy.pdf	31024 921ce6e61c952c1823067947e5ceba52 3798ed6d	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Miescher_DepotEffectOfCrys tal_PA.pdf	336622 587c006d0233f4e9d64f2a660b570ffbd 828b8c6	no	18
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Pieters_SustainedReleasePr operties_PA.pdf	407472 3d16534e949e8bea62b54f5013f072cd 806a5872	no	6
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Rodriguez-Spong_GeneralPr inciplesofPharmaceutical_PA .pdf	1776317 a0be9da6652082e429c2a1c8e8ad33a 83ab34889	no	34
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Schilffarth_AboutTheSympto maticTreatment_PA.pdf	93945 0930d812faf2009c98c2436efbf104268 0e26ef	no	11
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Shekunov_CrystallizationPro cessesinPharmaceutical_PA. pdf	863581 2df6d98d0f778d52ad5d4c1e6a90b75f a5f321a	no	15
<b>Warnings:</b>					

<b>Information:</b>					
9	NPL Documents	Singhal_DrugPolymorphismAndDosage_PA.pdf	738091 529c0311ffb697dfbe3c222ea3cd9ef8065aeee	no	13
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Vippagunta_CrystallineSolids_PA.pdf	1325167 496b964383d4e624fdca67c795f248db295bf8ca	no	24
<b>Warnings:</b>					
<b>Information:</b>					
11		VAND-0022_20080201_response.pdf	130111 6448c512fc0a8c986c58ed391ec42726b238b7c5	yes	13
<b>Multipart Description/PDF files in .zip description</b>					
<b>Document Description</b>			<b>Start</b>	<b>End</b>	
Amendment - After Non-Final Rejection			1	1	
Claims			2	8	
Applicant Arguments/Remarks Made in an Amendment			9	13	
<b>Warnings:</b>					
<b>Information:</b>					
12	Fee Worksheet (PTO-06)	fee-info.pdf	8180 838781ccac2d00b16051868c9c337b82bc99086a	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				6896681	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.